Systems Biology of Early Atopy

N/AActive Not RecruitingNCT04798079

National Institute of Allergy and Infectious Diseases (NIAID)2,500 enrolled

Overview

The goal of this study is to establish a birth cohort that collects prenatal and early life biosamples and environmental samples and rigorously phenotypes young children for food allergy and Atopic Dermatitis (AD) to identify prenatal and early life markers of high risk for food allergy and AD, as well as biological pathways (endotypes) that result in these conditions. Primary Objectives: * To study the role and interrelationships of established and novel clinical, environmental, biological, and genetic prenatal and early-life factors in the development and course of allergic diseases through age 3 years (or 6 years for those who choose to continue participation into SUNBEAM II), with an emphasis on atopic dermatitis and food allergy * To apply systems biology to identify mechanisms and biomarkers underlying the development of food allergy, atopic dermatitis, and their endotypes * To collect, process, and assay or store environmental and biological samples for current and future use in the study of allergic disease development

This is a prospective cohort study in which pregnant women (at any stage of pregnancy), the offspring's biologic father, and the offspring will be enrolled at study sites, and the offspring will be observed from birth to age 3 years. Enrollment of biological fathers will be attempted; however, enrollment of the mother or child is not dependent on enrollment of the biological father. The enrollment goal is at least 2500 mothers and their offspring having reached 12 months on study. Additionally, families will be offered the opportunity for the child participant to continue SUNBEAM through age 6 via the SUNBEAM II continuation protocol. During the study, biological and environmental samples and questionnaire information will be collected from the parents and the children, and the children will be assessed for allergic diseases at clinic visits at ages 2, 5, 12, 24, and 36 months and for those who opt to continue participation, at 48, 60, and 72 months.

Study Type

OBSERVATIONAL

Enrollment

2,500

Conditions

Allergic Diseases

Eligibility

Sex: ALLMin age: 0 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Pregnant Women- Pregnant women who meet all of the following criteria are eligible for enrollment as study participants: 1. Age 18 years or older 2. Able to understand the oral and written instructions associated with study visits and procedures and provide informed consent 3. Pregnant at any stage 4. Planning to give birth at a study-site designated center 5. Agrees to enroll offspring into the study at birth 6. In the case of multiple gestation, agrees to enroll only one child who will be selected by randomized birth order Biological Fathers- Biological fathers who meet all of the following criteria are eligible for enrollment as study participants: 1. Age 18 years or older 2. Able to understand the oral and written instructions associated with study visits and procedures and provide informed consent Exclusion Criteria: Pregnant Women- Pregnant women who meet any of these criteria are not eligible for enrollment: 1. Inability or unwillingness to comply with study protocol 2. Serious pregnancy complication (in the judgement of the investigator) prior to enrollment 3. Fetus has a major chromosomal anomaly 4. Plans to move and would not be available for in-person visits at a study site 5. Plans to give up her child for adoption at birth 6. Pregnancy is the result of an egg donation Infants- Infants who meet any of these criteria are not eligible for enrollment: 1. Delivered earlier than 34 weeks of gestation 2. Sibling already enrolled 3. Born with a significant birth defect or medical condition, and in the judgment of the investigators, participation is not in the infant's best interest Biological Father- 1\. Biological fathers who are unable or unwilling to comply with the study protocol as it pertains to the biological father's participation are not eligible for enrollment ----Note Regarding Legal Guardians who are not the Biological Parents: 1. At screening for enrollment of either the mother or the child, if the biological mother intends to give the infant up for adoption, neither the mother nor the child are eligible for enrollment 2. If the biological mother gives up legal guardianship of the child during the child's follow-up period, the child may remain enrolled as long as the new legal guardian: * Agrees to meet the child's study requirements, and * Provides written informed consent for the child's continued participation. 3. Throughout the protocol where it refers to the mother, father, or parent answering questionnaires about the child or collecting samples from the child and the child's primary home, the legal guardian who provides consent for the child's participation may complete those procedures

Locations (13)

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Sean N. Parker Center for Allergy & Asthma Research at Stanford University

Stanford, California, United States

National Jewish Health

Denver, Colorado, United States

Northwestern University Feinberg School of Medicine: Dept of Dermatology

Chicago, Illinois, United States

Johns Hopkins Children's Center, Department of Allergy & Immunology

Baltimore, Maryland, United States

Massachusetts General Hospital, Translational and Clinical Research Center

Boston, Massachusetts, United States

Henry Ford Health System, Division of Allergy and Immunology

Detroit, Michigan, United States

Kravis Children's Hospital, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai

New York, New York, United States

North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology

Chapel Hill, North Carolina, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

...and 3 more locations

Outcomes

Primary Outcomes

Incidence of Immunoglobulin E (IgE)-Mediated, Immediate-Type Food Allergy

To understand the early life origin and risk factors of child's IgE-mediated, immediate-type food allergy. Based upon clinical assessments and diagnostic criteria for food allergy, in accordance with the Food Allergy Algorithm, per protocol.

Time frame: From 5 months to 72 months of age

Incidence of Atopic Dermatitis (AD)

To understand the early life origin and risk factors of child's atopic dermatitis (AD). Atopic dermatitis is defined as the following since the last assessment (or since birth for the 2- and 5-month visits): 1. A history of a dry or itchy rash that is (a) either continuous or intermittent lasting at least 4 weeks OR (b) requiring medicated treatment AND 2. The rash was or is present in the skin creases (folds of elbows, behind the knees, fronts of ankles, or around the neck) or on the extensor aspects of the forearms or lower legs or on cheeks or trunk. Any infant fulfilling these criteria but who, on examination by a suitably trained health professional, is deemed to have a different skin disease that explains the above findings will be classified as not having atopic dermatitis.

Time frame: From 2 months to 72 months of age

Secondary Outcomes

Incidence of Sensitization to Protocol-Specified Foods

To understand the early life origin and risk factors of child's food allergy. Sensitization to food allergens will be assessed using standard diagnostic methods: serum immunoglobulin E (IgE) testing and skin prick testing.

Time frame: From 5 months to 72 months of age

Incidence of Sensitization to Aeroallergens

To understand the early life origin and risk factors of child's sensitization to aeroallergens, a risk factor for the development and severity of asthma. Sensitization to aeroallergens will be assessed using standard diagnostic methods: serum immunoglobulin E (IgE) testing and skin prick testing.

Time frame: From 12 months to 72 months of age

Incidence of Recurrent Wheeze

To understand the early life origin and risk factors of child's recurrent wheezing. Recurrent wheeze, assessed at age 3 years, will be defined as at least two episodes of wheezing during the first three years of life, with at least one episode between the ages of 24 and 36 months

Time frame: Up to 36 months of age

Incidence of Seasonal Allergic Rhinitis

To understand the early life origin and risk factors of child's seasonal allergic rhinitis, a seasonal allergic reaction to pollen. Defined by diagnostic criteria established for the Inner-City Asthma Consortium, per protocol.

Time frame: From 24 to 72 months of age

Incidence of Seasonal Allergic Conjunctivitis

To understand the early life origin and risk factors of child's seasonal allergic conjunctivitis, a form of eye allergy. Defined by diagnostic criteria established for the Inner-City Asthma Consortium, per protocol.

Time frame: From 24 to 72 months of age

Incidence of Perennial Allergic Rhinitis

To understand the early life origin and risk factors of child's perennial allergic rhinitis, characterized by nasal symptoms such as sneezing and runny nose that are present year round. Defined by diagnostic criteria established for the Inner-City Asthma Consortium, per protocol.

Time frame: From 24 to 72 months of age

Incidence of Perennial Allergic Conjunctivitis

Time frame: From 24 to 72 months of age

Incidence of Asthma

To understand the early life origin and risk factors of child's asthma, characterized by wheezing and other respiratory symptoms. The determination of asthma will follow criteria from the Urban Environment and Childhood Asthma (URECA) study.

Time frame: 72 months of age